Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer

Erasca (ERAS) and Bristol Myers Squibb (BMY) will collaborate on a Phase 1/2 trial to study ERAS-0015 and navlimetostat in MTAP-deleted pancreatic cancer. ERAS-0015 targets RAS, while navlimetostat inhibits PRMT5. Erasca will supply the drug, and BMY will sponsor the study. ERAS stock closed at $13.89, up 3.05% in after-hours trading.

Original reporting
Published Nov 18, 2026, 4:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 4:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer — source image
Decision brief

The 30-second read

$ERASBullishMed
01

Why it matters

The announcement provides Erasca with validation and potential funding, while BMY expands its early‑stage pipeline. Both stocks may experience short‑term price bumps, but long‑term impact depends on trial outcomes.

02

Market read

First‑report of a biotech‑big‑pharma partnership, offering a fresh catalyst for both ERAS and BMY, with modest but positive market implications.

03

What to watch

The trial targets a rare MTAP‑deleted subset, limiting market size; regulatory timelines remain uncertain.

Relevance 7/10Novelty 7/10Timing: today, after‑hours release

Background

Erasca is a micro‑cap biotech focused on pan‑RAS molecular glues. Bristol Myers Squibb is a large, diversified oncology player. The collaboration combines two investigational agents for a specific genetic subtype of pancreatic cancer.

Company-level read

Ticker impact

$ERASBullishHigh confidence
Context

Erasca announced a new Phase 1/2 trial partnership with Bristol Myers Squibb to test its pan‑RAS molecular glue ERAS‑0015 in MTAP‑deleted pancreatic cancer.

Expected impact

upward pressure as investors price in potential clinical success and partnership validation

Evidence & confidence

First‑report partnership with a large pharma partner (BMY) adds credibility and may accelerate development, a material catalyst for a micro‑cap biotech.

$BMYBullishMedium confidence
Context

Bristol Myers Squibb will sponsor a Phase 1/2 study combining its PRMT5 inhibitor navlimetostat with Erasca's ERAS‑0015 for MTAP‑deleted pancreatic cancer.

Expected impact

slight upward pressure as the market sees expansion of BMY's oncology portfolio

Evidence & confidence

While BMY is a large, diversified company, new early‑stage oncology collaborations are generally welcomed but have limited immediate impact.

Market effects

Highlights growing interest in pan‑RAS and PRMT5 inhibition strategies, potentially boosting biotech and oncology sector sentiment.

U.S. biotech and pharma stocks may see modest gains as investors reassess pipeline collaborations.

Adds to the global trend of big pharma partnering with niche biotech firms to de‑risk early‑stage oncology programs.

Counterpoint

Early‑stage trial data may be disappointing; partnership could dilute Erasca's valuation if milestones are missed.

Key entities

  • Erasca, Inc.

    Developer of ERAS‑0015, a pan‑RAS molecular glue.

  • Bristol Myers Squibb

    Pharma giant sponsoring the combination trial with its PRMT5 inhibitor navlimetostat.

Related articles

$BMYMed

Bristol Myers Squibb shares preliminary KarXT trial data

Bristol Myers Squibb (BMY) presented preliminary Phase 3 data from its ADEPT trials for KarXT in treating psychosis related to Alzheimer’s disease. The studies showed mean reductions in hallucinations and delusions, with adverse events reported. KarXT is FDA-approved for schizophrenia. No treatments are currently approved for Alzheimer’s-related psychosis.

$BMYMed

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

Bristol Myers Squibb (BMY) shared preliminary Phase 3 data for KarXT in treating psychosis linked to Alzheimer's. ADEPT-1 showed improvements in hallucination and delusion scores over 12 weeks. ADEPT-3 reported long-term safety and tolerability data over 52 weeks. Both studies observed symptom score improvements and a favorable safety profile.

$MRKMedAI 8/10

AHA 2026: Pharmacists at the Center of Cardiometabolic Care

At AHA 2026, data on new cardiometabolic therapies highlighted pharmacists' growing role. Survodutide (Zealand Pharma, Boehringer Ingelheim) showed cardiovascular safety. Enlicitide (Merck) sustained LDL-C reductions. Stanford's model embedded pharmacists in heart failure care. Orforglipron (Eli Lilly) lowered systolic blood pressure. Pharmacists were noted for their critical roles in titration, adherence, and monitoring.

$BMYHigh

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb (BMY) is expanding its cardiovascular franchise with label expansions for Camzyos, including pediatric approvals, driving sales growth. Camzyos sales surged 61% YoY to $1.1B in 9 months. Eliquis, a key revenue driver, saw $13.3B in sales, up 21% YoY. BMY faces competition from Cytokinetics (CYTK) and Edgewise Therapeutics (EWTX) in the oHCM market. BMY shares gained 15.5% YTD, trading at 9.52X forward earnings.

$GSKMedAI 8/10

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.